Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Quantifying Drug Combination Synergy along Potency and Efficacy Axes.

Meyer CT, Wooten DJ, Paudel BB, Bauer J, Hardeman KN, Westover D, Lovly CM, Harris LA, Tyson DR, Quaranta V.

Cell Syst. 2019 Feb 27;8(2):97-108.e16. doi: 10.1016/j.cels.2019.01.003. Epub 2019 Feb 20.

PMID:
30797775
2.

Correction: Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer.

Hanker AB, Estrada MV, Bianchini G, Moore PD, Zhao J, Cheng F, Koch JP, Gianni L, Tyson DR, Sánchez V, Rexer BN, Sanders ME, Zhao Z, Stricker TP, Arteaga CL.

Cancer Res. 2019 Feb 15;79(4):873. doi: 10.1158/0008-5472.CAN-18-4085. No abstract available.

PMID:
30770368
3.

A Nonquiescent "Idling" Population State in Drug-Treated, BRAF-Mutated Melanoma.

Paudel BB, Harris LA, Hardeman KN, Abugable AA, Hayford CE, Tyson DR, Quaranta V.

Biophys J. 2018 Mar 27;114(6):1499-1511. doi: 10.1016/j.bpj.2018.01.016.

4.

A drift-diffusion checkpoint model predicts a highly variable and growth-factor-sensitive portion of the cell cycle G1 phase.

Jones ZW, Leander R, Quaranta V, Harris LA, Tyson DR.

PLoS One. 2018 Feb 12;13(2):e0192087. doi: 10.1371/journal.pone.0192087. eCollection 2018.

5.

A Predictive Mathematical Modeling Approach for the Study of Doxorubicin Treatment in Triple Negative Breast Cancer.

McKenna MT, Weis JA, Barnes SL, Tyson DR, Miga MI, Quaranta V, Yankeelov TE.

Sci Rep. 2017 Jul 18;7(1):5725. doi: 10.1038/s41598-017-05902-z.

6.

Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer.

Hanker AB, Estrada MV, Bianchini G, Moore PD, Zhao J, Cheng F, Koch JP, Gianni L, Tyson DR, Sánchez V, Rexer BN, Sanders ME, Zhao Z, Stricker TP, Arteaga CL.

Cancer Res. 2017 Jun 15;77(12):3280-3292. doi: 10.1158/0008-5472.CAN-16-2808. Epub 2017 Apr 10. Erratum in: Cancer Res. 2019 Feb 15;79(4):873.

7.

Dependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition.

Hardeman KN, Peng C, Paudel BB, Meyer CT, Luong T, Tyson DR, Young JD, Quaranta V, Fessel JP.

Sci Rep. 2017 Feb 16;7:42604. doi: 10.1038/srep42604.

8.

Altered TGF-α/β signaling drives cooperation between breast cancer cell populations.

Franco OE, Tyson DR, Konvinse KC, Udyavar AR, Estrada L, Quaranta V, Crawford SE, Hayward SW.

FASEB J. 2016 Oct;30(10):3441-3452. Epub 2016 Jul 6.

9.

An unbiased metric of antiproliferative drug effect in vitro.

Harris LA, Frick PL, Garbett SP, Hardeman KN, Paudel BB, Lopez CF, Quaranta V, Tyson DR.

Nat Methods. 2016 Jun;13(6):497-500. doi: 10.1038/nmeth.3852. Epub 2016 May 2.

10.

Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.

Wirtz ED, Hoshino D, Maldonado AT, Tyson DR, Weaver AM.

JAMA Otolaryngol Head Neck Surg. 2015 Jun;141(6):543-9. doi: 10.1001/jamaoto.2015.0471.

11.

Quantifying heterogeneity and dynamics of clonal fitness in response to perturbation.

Frick PL, Paudel BB, Tyson DR, Quaranta V.

J Cell Physiol. 2015 Jul;230(7):1403-12. doi: 10.1002/jcp.24888.

12.

Derivation and experimental comparison of cell-division probability densities.

Leander R, Allen EJ, Garbett SP, Tyson DR, Quaranta V.

J Theor Biol. 2014 Oct 21;359:129-35. doi: 10.1016/j.jtbi.2014.06.004. Epub 2014 Jun 12.

13.

Beyond genetics in personalized cancer treatment: assessing dynamics and heterogeneity of tumor responses.

Tyson DR, Quaranta V.

Per Med. 2013 May 1;10(3):221-225. No abstract available.

14.

Reverse-phase protein array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer.

Sewell A, Brown B, Biktasova A, Mills GB, Lu Y, Tyson DR, Issaeva N, Yarbrough WG.

Clin Cancer Res. 2014 May 1;20(9):2300-11. doi: 10.1158/1078-0432.CCR-13-2585. Epub 2014 Mar 5.

15.

What lies beneath: looking beyond tumor genetics shows the complexity of signaling networks underlying drug sensitivity.

Quaranta V, Tyson DR.

Sci Signal. 2013 Sep 24;6(294):pe32. doi: 10.1126/scisignal.2004715. Review.

PMID:
24065144
16.

Network analysis of the focal adhesion to invadopodia transition identifies a PI3K-PKCα invasive signaling axis.

Hoshino D, Jourquin J, Emmons SW, Miller T, Goldgof M, Costello K, Tyson DR, Brown B, Lu Y, Prasad NK, Zhang B, Mills GB, Yarbrough WG, Quaranta V, Seiki M, Weaver AM.

Sci Signal. 2012 Sep 11;5(241):ra66. doi: 10.1126/scisignal.2002964.

17.

Fractional proliferation: a method to deconvolve cell population dynamics from single-cell data.

Tyson DR, Garbett SP, Frick PL, Quaranta V.

Nat Methods. 2012 Sep;9(9):923-8. doi: 10.1038/nmeth.2138. Epub 2012 Aug 12.

18.

Inhibition of phosphodiesterase-4 (PDE4) activity triggers luminal apoptosis and AKT dephosphorylation in a 3-D colonic-crypt model.

Tsunoda T, Ota T, Fujimoto T, Doi K, Tanaka Y, Yoshida Y, Ogawa M, Matsuzaki H, Hamabashiri M, Tyson DR, Kuroki M, Miyamoto S, Shirasawa S.

Mol Cancer. 2012 Jul 25;11:46. doi: 10.1186/1476-4598-11-46.

19.

The contribution of age structure to cell population responses to targeted therapeutics.

Gabriel P, Garbett SP, Quaranta V, Tyson DR, Webb GF.

J Theor Biol. 2012 Oct 21;311:19-27. doi: 10.1016/j.jtbi.2012.07.001. Epub 2012 Jul 11.

20.

Composite thin film and electrospun biomaterials for urologic tissue reconstruction.

Kundu AK, Gelman J, Tyson DR.

Biotechnol Bioeng. 2011 Jan;108(1):207-15. doi: 10.1002/bit.22912.

PMID:
20830673
21.

Trait variability of cancer cells quantified by high-content automated microscopy of single cells.

Quaranta V, Tyson DR, Garbett SP, Weidow B, Harris MP, Georgescu W.

Methods Enzymol. 2009;467:23-57. doi: 10.1016/S0076-6879(09)67002-6.

22.

Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness.

Finley DS, Calvert VS, Inokuchi J, Lau A, Narula N, Petricoin EF, Zaldivar F, Santos R, Tyson DR, Ornstein DK.

J Urol. 2009 Oct;182(4):1621-7. doi: 10.1016/j.juro.2009.06.015. Epub 2009 Aug 15.

PMID:
19683746
23.

Loss of annexin A1 disrupts normal prostate glandular structure by inducing autocrine IL-6 signaling.

Inokuchi J, Lau A, Tyson DR, Ornstein DK.

Carcinogenesis. 2009 Jul;30(7):1082-8. doi: 10.1093/carcin/bgp078. Epub 2009 Apr 7.

24.

Long-term impact of a robot assisted laparoscopic prostatectomy mini fellowship training program on postgraduate urological practice patterns.

Gamboa AJ, Santos RT, Sargent ER, Louie MK, Box GN, Sohn KH, Truong H, Lin R, Khosravi A, Santos R, Ornstein DK, Ahlering TE, Tyson DR, Clayman RV, McDougall EM.

J Urol. 2009 Feb;181(2):778-82. doi: 10.1016/j.juro.2008.10.018. Epub 2008 Dec 16.

PMID:
19091351
25.

Annexin A2 positively contributes to the malignant phenotype and secretion of IL-6 in DU145 prostate cancer cells.

Inokuchi J, Narula N, Yee DS, Skarecky DW, Lau A, Ornstein DK, Tyson DR.

Int J Cancer. 2009 Jan 1;124(1):68-74. doi: 10.1002/ijc.23928.

26.

Bone marrow stem cells for urologic tissue engineering.

Shukla D, Box GN, Edwards RA, Tyson DR.

World J Urol. 2008 Aug;26(4):341-9. doi: 10.1007/s00345-008-0311-y. Epub 2008 Jul 25.

PMID:
18654786
27.

Proteomics of cancer of hormone-dependent tissues.

Tyson DR, Ornstein DK.

Adv Exp Med Biol. 2008;630:133-47. Review.

PMID:
18637489
28.
29.

The impact of altered annexin I protein levels on apoptosis and signal transduction pathways in prostate cancer cells.

Hsiang CH, Tunoda T, Whang YE, Tyson DR, Ornstein DK.

Prostate. 2006 Sep 15;66(13):1413-24.

PMID:
16741918
30.

Proteomics for the identification of new prostate cancer biomarkers.

Ornstein DK, Tyson DR.

Urol Oncol. 2006 May-Jun;24(3):231-6. Review.

PMID:
16678055
31.

Human embryonic kidney cells (HEK-293 cells): characterization and dose-response relationship for modulated release of nerve growth factor for nerve regeneration.

Jimenez JC, Tyson DR, Dhar S, Nguyen T, Hamai Y, Bradshaw RA, Evans GR.

Plast Reconstr Surg. 2004 Feb;113(2):605-10.

PMID:
14758223
32.

O-sulfonation of serine and threonine: mass spectrometric detection and characterization of a new posttranslational modification in diverse proteins throughout the eukaryotes.

Medzihradszky KF, Darula Z, Perlson E, Fainzilber M, Chalkley RJ, Ball H, Greenbaum D, Bogyo M, Tyson DR, Bradshaw RA, Burlingame AL.

Mol Cell Proteomics. 2004 May;3(5):429-40. Epub 2004 Jan 29.

33.

PC12 cell activation by epidermal growth factor receptor: role of autophosphorylation sites.

Tyson DR, Larkin S, Hamai Y, Bradshaw RA.

Int J Dev Neurosci. 2003 Apr;21(2):63-74.

PMID:
12615082
34.

Induction of transcriptional activity of the cyclic adenosine monophosphate response element binding protein by parathyroid hormone and epidermal growth factor in osteoblastic cells.

Swarthout JT, Tyson DR, Jefcoat SC Jr, Partridge NC.

J Bone Miner Res. 2002 Aug;17(8):1401-7. Erratum in: J Bone Miner Res. 2002 Oct;17(10):1917. Efcoat, Stephen CJ Jr [corrected to Jefcoat, Stephen CJ Jr].

36.

Role of GATA motifs in tissue factor pathway inhibitor gene expression in malignant cells.

Bajaj MS, Tyson DR, Steer SA, Kuppuswamy MN.

Thromb Res. 2001 Feb 1;101(3):203-11.

PMID:
11228343
37.
39.

Parathyroid hormone versus phorbol ester stimulation of activator protein-1 gene family members in rat osteosarcoma cells.

Koe RC, Clohisy JC, Tyson DR, Pulumati MR, Cook TF, Partridge NC.

Calcif Tissue Int. 1997 Jul;61(1):52-8.

PMID:
9192514
40.

Revised DNA sequence of exon 1 and 5' flanking region of the human tissue factor pathway inhibitor gene.

Tyson DR, Kuppuswamy MN, Broze GJ Jr, Bajaj SP.

Thromb Res. 1993 May 1;70(3):269-73. No abstract available.

PMID:
8327992
41.

The association of aberrant renal arteries and systemic hypertension.

DERRICK JR, TYSON DR.

Surgery. 1960 Nov;48:907-12. No abstract available.

PMID:
13722090

Supplemental Content

Loading ...
Support Center